Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood-derived megakaryocyte injection
- Development stage
- Unknown
- Lead developer
- Xueji Bio
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord blood-derived megakaryocyte injection (XJ-01) is a first-in-class cell therapy developed by Xueji Biopharma for the treatment of chemotherapy-induced thrombocytopenia (CIT). The therapy consists of mature megakaryocytes derived from hematopoietic stem cells (HSCs) found in umbilical cord blood, which are expanded and differentiated *ex vivo*. Unlike traditional platelet transfusions that provide a short-term increase in platelet levels, this injection delivers the precursor cells responsible for platelet production. Once administered, these megakaryocytes are designed to home to the patient's bone marrow and continuously release functional platelets into the bloodstream, potentially offering a more rapid and durable recovery of platelet counts and reducing the risk of bleeding in patients with bone marrow suppression.
- Other names
- umbilical cord blood-derived megakaryocyte injection脐带血来源巨核细胞注射液
Beyond the preview
Go deeper on umbilical cord blood-derived megakaryocyte injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood-derived megakaryocyte injection.